Moreover, adenomyosis is a chronic inflammatory disease requiring long-term administration of TGF-β inhibitors, which increases the risk of impaired wound healing, vascular defects, immune dysregulation, or tumorigenesis (Frangogiannis, 2020). Here, TGFB1 is linked to adenomyosis.